Norgestrel

CAS# 6533-00-2

Norgestrel

Catalog No. BCN9638----Order now to get a substantial discount!

Product Name & Size Price Stock
Norgestrel: 5mg $17 In Stock
Norgestrel: 10mg Please Inquire In Stock
Norgestrel: 20mg Please Inquire Please Inquire
Norgestrel: 50mg Please Inquire Please Inquire
Norgestrel: 100mg Please Inquire Please Inquire
Norgestrel: 200mg Please Inquire Please Inquire
Norgestrel: 500mg Please Inquire Please Inquire
Norgestrel: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Norgestrel

Number of papers citing our products

Chemical structure

Norgestrel

3D structure

Chemical Properties of Norgestrel

Cas No. 6533-00-2 SDF Download SDF
PubChem ID 126968545 Appearance Powder
Formula C21H28O2 M.Wt 312.4
Type of Compound Impurities Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (8S,10R,13S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
SMILES CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Standard InChIKey WWYNJERNGUHSAO-YHKGGNDHSA-N
Standard InChI InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17?,18-,19?,20-,21-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Norgestrel Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Norgestrel Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Norgestrel

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.201 mL 16.0051 mL 32.0102 mL 64.0205 mL 80.0256 mL
5 mM 0.6402 mL 3.201 mL 6.402 mL 12.8041 mL 16.0051 mL
10 mM 0.3201 mL 1.6005 mL 3.201 mL 6.402 mL 8.0026 mL
50 mM 0.064 mL 0.3201 mL 0.6402 mL 1.2804 mL 1.6005 mL
100 mM 0.032 mL 0.1601 mL 0.3201 mL 0.6402 mL 0.8003 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
 

References on Norgestrel

Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis.[Pubmed:32481439]

Medicine (Baltimore). 2020 May 29;99(22):e20421.

To evaluate the efficacy and feasibility of levoNorgestrel-releasing intrauterine device (LNG-IUD) use longer than 5 years in women with adenomyosis.Data were retrospectively collected from patients who were treated with LNG-IUD longer than 5 years at the Chungnam National University hospital for adenomyosis diagnosed with ultrasonography from January 2006 to November 2013.A total of 131 patients who were diagnosed with adenomyosis had treated with LNG-IUD longer than 5 years. The mean duration of keeping 1 device without replacement was 58.35 +/- 15.98 months, and total duration of LNG-IUD treatment was 83.86 +/- 23.88 months. A total of 51 patients stopped using LNG-IUD after 5 years and the mean age at the time of LNG-IUD removal was 52.46 +/- 6.9. LNG-IUD treatment had a significant effect on both menorrhagia and dysmenorrhea starting from the first month of insertion (P < .01), which persisted until 6 years when the effect started to plateau. The decrease in uterine volume was not consistent during the treatment period. The uterine volume decreased significantly only in the first and second year of LNG-IUD treatment and then from eighth to tenth year of LNG-IUD treatment (P < .05). Adverse events after insertion of LNG-IUD decreased significantly after 5 years.LNG-IUD treatment longer than 5 years is an effective and feasible method for patients diagnosed with adenomyosis.

Deep eutectic solvent-based magnetic colloidal gel assisted magnetic solid-phase extraction: A simple and rapid method for the determination of sex hormones in cosmetic skin care toners.[Pubmed:32417516]

Chemosphere. 2020 Sep;255:127004.

A simple rapid and efficient deep eutectic solvent-based magnetic colloidal gel (DES-MCG) assisted magnetic solid-phase extraction (MSPE) method followed by high performance liquid chromatography with a diode array detector (HPLC-DAD) was established for determination of four sex hormones (including ethinylestradiol, Norgestrel, megestrol acetate and medroxyprogesterone acetate) in cosmetic skin care toners. The DES-MCG with the desirable advantages of high adsorbing ability was prepared by combining choline chloride/urea deep eutectic solvent and magnetic multiwalled carbon nanotubes (MMWCNTs). The synthesized DES-MCG was characterized using fourier transform infrared spectrometry (FTIR), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and vibrating sample magnetometry (VSM). The cosmetic skin care toners were concentrated by a rotary evaporator and the obtained solutions were further purified by DES-MCG assisted magnetic solid-phase extraction. Response surface methodology (RSM) was applied for efficient optimization of the main variables in the extraction procedure. Under the optimized conditions, method detection limits and method quantitation limits were in the range of 1.2-6.6 ng mL(-1) and 4.4-26.6 ng mL(-1), respectively. The recoveries of the four sex hormones in different cosmetic skin care toners ranged from 80.1% to 118.8% and the precisions were no more than 0.35%. The developed method was successfully applied for the determination of sex hormones in cosmetic skin care toners.

[Effects of LNG-IUS on sexual function and sexual quality in women of childbearing age].[Pubmed:32344499]

Zhonghua Yi Xue Za Zhi. 2020 Apr 28;100(16):1255-1259.

Objective: To investigate the effects of levoNorgestrel releasing intrauterine system (LNG-IUS) on sexual function and sexual quality in women of childbearing age. Methods: A total of 203 healthy women who were using IUD for long-term contraception were enrolled in the study. Among them, 130 were placed LNG-IUS as the study group and 73 were placed the copper intrauterine devices (Cu-IUDs) as the control group. The two groups were further divided into three subgroups by age. The basic information and questionnaires were adopted before and 2 years after using IUDs, including age, the time of using IUD, side-effects after using IUD, frequency and satisfaction of sex after using IUD. The Female Sexual Function Index (FSFI) was evaluated on 2 years after. Results: In the 30-39 age subgroup, the frequency of sex was significantly decreased after using LNG-IUS (P<0.05). Rests of the subgroup shows no significantly different in the frequency of sex (P>0.05). The sexual satisfaction in all subgroups also shows no significantly different before and after using IUDs (P>0.05). There was no significant difference in the individual score and total scores of FSFI between the study group and control group (P>0.05). Conclusion: The LNG-IUS has no adverse effects on female sexual function and sexual quality in the reproductive age.

Sorption and desorption of seven steroidal synthetic progestins in five agricultural soil-water systems.[Pubmed:32272348]

Ecotoxicol Environ Saf. 2020 Jun 15;196:110586.

Manure fertilization and wastewater irrigation can introduce the biologically potent synthetic progestins into agricultural soils, causing endocrine disruption in organisms of nearby surface waters. Therefore, this study investigated the sorption and desorption potential of etonogestrel, medroxyprogesterone, gestodene, Norgestrel, cyproterone acetate, levoNorgestrel, and dienogest in five agricultural soil-water systems. Sorption data were well-described by the linear sorption model. In most batch systems, cyproterone acetate exhibited the highest affinities for soils, followed by etonogestrel, medroxyprogesterone, levoNorgestrel, gestodene, Norgestrel, and dienogest. The sorption magnitudes (logKoc or logKd) were significantly correlated with the progestin hydrophobicities (R(2) = 0.72-0.86, p < 0.05). The Kd values of the progestins were also significantly correlated with organic carbon content and pore volumes of the soils (R(2) = 0.68-0.98, p < 0.05). In addition, 0.5 M urea resulted in 3-19% decreases in Kd values of the progestins. Taken together, these data indicated that hydrophobic partitioning interaction, hydrogen bonding interaction, and pore filling were the sorption mechanisms for the progestins in soil-water systems. No significant desorption hysteresis was observed for the progestins, indicating that they can be readily desorbed under rainfall or irrigation events. Based on the sorption and desorption data, we estimated the dynamic transport of the progestins in conventional agricultural management systems, and predicted the concentrations of the progestins as a function of soil-sorbed concentration, water-soil ratio, and dilution factor of receiving waters. This study will improve the understanding of the risks posed by the progestins under field-scale hydrological conditions.

Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.[Pubmed:31923062]

Obstet Gynecol. 2020 Feb;135(2):319-327.

OBJECTIVE: To evaluate the relative risk of cervical neoplasms among copper intrauterine device (Cu IUD) and levoNorgestrel-releasing intrauterine system (LNG-IUS) users. METHODS: We performed a retrospective cohort analysis of 10,674 patients who received IUDs at Columbia University Medical Center. Our data were transformed to a common data model and are part of the Observational Health Data Sciences and Informatics network. The cohort patients and outcomes were identified by a combination of procedure codes, condition codes, and medication exposures in billing and claims data. We adjusted for confounding with propensity score stratification and propensity score 1:1 matching. RESULTS: Before propensity score adjustment, the Cu IUD cohort included 8,274 patients and the LNG-IUS cohort included 2,400 patients. The median age for both cohorts was 29 years at IUD placement. More than 95% of the LNG-IUS cohort used a device with 52 mg LNG. Before propensity score adjustment, we identified 114 cervical neoplasm outcomes. Seventy-seven (0.9%) cervical neoplasms were in the Cu IUD cohort and 37 (1.5%) were in the LNG-IUS cohort. The propensity score matching analysis identified 7,114 Cu IUD and 2,174 LNG-IUS users, with covariate balance achieved over 16,827 covariates. The diagnosis of high-grade cervical neoplasia was 0.7% in the Cu IUD cohort and 1.8% in the LNG-IUS cohort (2.4 [95% CI 1.5-4.0] cases/1,000 person-years and 5.2 [95% CI 3.7-7.1] cases/1,000 person-years, respectively). The relative risk of high-grade cervical neoplasms among Cu IUD users was 0.38 (95% CI 0.16-0.78, P<.02) compared with LNG-IUS users. By inspection, the Kaplan-Meier curves for each cohort diverged over time. CONCLUSION: Copper IUD users have a lower risk of high-grade cervical neoplasms compared with LNG-IUS users. The relative risk of cervical neoplasms of LNG-IUS users compared with the general population is unknown.

Keywords:

Norgestrel,6533-00-2,Natural Products, buy Norgestrel , Norgestrel supplier , purchase Norgestrel , Norgestrel cost , Norgestrel manufacturer , order Norgestrel , high purity Norgestrel

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: